OVID_OUT_1 [2025-04-02 19:22:36 -0400] 2322 Bytes | 636 tokens | Cum: 636 tkns (7.95% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Ovid Therapeutics (OVID) which is at 0.357 up from 0.3097. So, I pulled together a bunch of data for you to look over real fast. It's still early, 7:22:36 PM on Wed Apr 02, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Ovid Therapeutics (OVID)
IPO: IPO date unknown
Shares Outstanding: 71,080,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Ovid Therapeutics:

C1 - Today 08:00AM - Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
C2 - Mar-11-25 09:10AM - Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
C3 - Mar-11-25 09:10AM 08:00AM - Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
C4 - Mar-03-25 08:00AM - Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
C5 - Feb-27-25 08:00AM - Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
C6 - Feb-05-25 08:00AM - Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
C7 - Jan-30-25 09:55AM - Ovid Therapeutics upgraded at Oppenheimer as OV329s promise quite real
C8 - Dec-02-24 08:00AM - Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Ovid Therapeutics (OVID)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

OVID_OUT_3 [2025-04-02 19:22:41 -0400] 1098 Bytes | 301 tokens | Cum: 939 tkns (11.74% of 8k)
==========================================================================

Showing C2 (chunk 1 of 5): C2:
**Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates**
Date: Mar-11-25 09:10AM
Source: (Zacks)
URL: https://finance.yahoo.com/news/ovid-therapeutics-ovid-reports-q4-131003037.html

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.20, delivering a surprise of -5.26%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Ovid Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.08 million for the quarter end

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OVID_OUT_5 [2025-04-02 19:22:42 -0400] 952 Bytes | 271 tokens | Cum: 1333 tkns (16.66% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T12:34:41Z - Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference | Taiwan News ...
A2 - 2025-04-02T12:15:56Z - Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2...
A3 - 2025-04-02T12:16:00Z - Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference...
A4 - 2025-04-02T12:00:00Z - Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Ovid Therape...
A5 - 2025-03-31T13:00:53Z - Texas measles cases jump 20%...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OVID_OUT_7 [2025-04-02 19:22:46 -0400] 1098 Bytes | 304 tokens | Cum: 1639 tkns (20.49% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference | Taiwan News | Apr. 2, 2025 20:00**Date: 2025-04-02Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6075801NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET.

A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Compa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OVID_OUT_9 [2025-04-02 19:22:47 -0400] 1057 Bytes | 329 tokens | Cum: 2048 tkns (25.60% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-27T13:00:00Z - Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
B2 - 2025-02-20T18:00:00Z - Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight
B3 - 2025-02-05T13:00:00Z - Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
B4 - 2024-07-01T12:00:00Z - Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
B5 - 2024-06-30T13:10:33Z - Wall Street Breakfast: The Week Ahead
B6 - 2024-06-20T15:39:00Z - Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OVID_OUT_11 [2025-04-02 19:22:49 -0400] 765 Bytes | 206 tokens | Cum: 2256 tkns (28.20% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/27/3033769/0/en/Ovid-Therapeutics-to-Present-at-the-TD-Cowen-45th-Annual-Health-Care-Conference.htmlOvid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OVID_OUT_13 [2025-04-02 19:22:50 -0400] 799 Bytes | 202 tokens | Cum: 2528 tkns (31.60% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-11 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussi...

S2 - 2025-03-11 8-K Item 2.02. Results of Oper and Fin Cond.

On March 11, 2025, Ovid Therapeutics Inc. (the Company) issued a press release announcing Business Updates and Fourth Quarter and Full Year 2024 Fin Results. A copy of the press release is furnished as Exhibit 99.1...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OVID_OUT_15 [2025-04-02 19:22:51 -0400] 1098 Bytes | 227 tokens | Cum: 2757 tkns (34.46% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Risk Factors and elsewhere in this Annual Report on Form 10-K. You should carefully read the Risk Factors section of th

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OVID_OUT_17 [2025-04-02 19:22:58 -0400] 5395 Bytes | 1609 tokens | Cum: 4368 tkns (54.60% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 166,658 | Perf Month: -33.33% | Option/Short: Yes / Yes | Sales Y/Y TTM: 44.50% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 426.95K | Perf Quarter: -64.48% | Short Float: 1.88% | ROE: -33.88% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 0.39 | Index: RUT | Short Ratio: 2.49 | ROI: -32.37% |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 29.96 | Market Cap: 24.16M | Short Interest: 1.06M | Sales Surprise: -60.08% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.05 | Shs Outstand: 71.01M | Beta: 0.28 | EPS Surprise: 22.94% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -21.15% | Shs Float: 56.63M | Sales Q/Q: -46.31% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -38.15% | Inst Own: 52.49% | Sales past 5Y: 284.57% | Earnings: Mar 11 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -63.45% | Insider Own: 20.33% | Employees: 23 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -16.46% | Insider Trans: -0.02% | Debt/Eq: 0.22 | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

Inside Trans: Ovid Therapeutics Inc. (OVID) by PAPADOPOULOS STELIOS (Unknown Title) on 2025-03-03
- Stock Option (right to buy): 90000 shares at $0 (D)

Inside Trans: Ovid Therapeutics Inc. (OVID) by Rona Jeffrey A (CBFO) on 2025-02-26
- Common Stock: 3902 shares at $0.56 (D)

Inside Trans: Ovid Therapeutics Inc. (OVID) by ALEXANDER MARGARET A. (President and COO) on 2025-02-26
- Common Stock: 5279 shares at $0.56 (D)

Inside Trans: Ovid Therapeutics Inc. (OVID) by ALEXANDER MARGARET A. (President and COO) on 2025-02-20
- Common Stock: 43750 shares at $0 (D)
- Employee Stock Option (Right to Buy): 262500 shares at $0 (D)

Inside Trans: Ovid Therapeutics Inc. (OVID) by Rona Jeffrey A (CBFO) on 2025-02-20
- Common Stock: 43750 shares at $0 (D)
- Employee Stock Option (Right to Buy): 262500 shares at $0 (D)

Inside Trans: Ovid Therapeutics Inc. (OVID) by LEVIN JEREMY M (CEO) on 2025-02-20
- Employee Stock Option (Right to Buy): 1650000 shares at $0 (D)

Inside Trans: Ovid Therapeutics Inc. (OVID) by ALEXANDER MARGARET A. (President and COO) on 2025-01-27
- Common Stock: 6810 shares at $0.73 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 566000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -26433000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.34
Average Volume: 391929.91
30-Day High: 0.5195
30-Day Low: 0.3097

[Detailed Financials: TTM 2024]
- Total Assets: $92,167,000.0
- Total Liabilities: $23,941,000.0
- Total Equity: $68,226,000.0
- Current Assets: $55,940,000.0
- Current Liabilities: $10,522,000.0

[Income Statement: TTM 2024]
- Revenue: $566,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-740,000

[Detailed Financials: FY 2024]
- Total Assets: $92,167,000.0
- Total Liabilities: $23,941,000.0
- Total Equity: $68,226,000.0
- Current Assets: $55,940,000.0
- Current Liabilities: $10,522,000.0

[Income Statement: FY 2024]
- Revenue: $566,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-740,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

OVID_OUT_19 [2025-04-02 19:23:00 -0400] 676 Bytes | 167 tokens | Cum: 4741 tkns (59.26% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

OVID_IN_21 [2025-04-02 19:23:00 -0400] 126 Bytes | 29 tokens | Cum: 4798 tkns (59.98% of 8k)
==========================================================================

====================================
[2025-04-02 19:23:00] # Analysis Completed
Elapsed Time: 24.53 seconds